

**IN THE CLAIMS**

1. (Currently amended) ~~A pharmaceutical tablet comprising fosinopril sodium and the lubricant zinc stearate wherein the presence of the lubricant results in a significant reduction in products of degradation for the tablet in comparison to other known lubricants such as magnesium stearate, and calcium stearate.~~ **A pharmaceutical tablet comprising fosinopril sodium and zinc stearate as lubricant, wherein the rate of degradation of fosinopril sodium is reduced relative to the same fosinopril sodium tablet but comprising as lubricant magnesium stearate, or calcium stearate, instead of zinc stearate as lubricant.**

Claims 2 to 5 (cancelled)

6. (Previously amended) The tablet of claim 1 further comprising lactose.

7. (Currently amended) ~~A~~ **The** tablet ~~as in~~ **of** claim 1 wherein the amount of lubricant **zinc stearate** by weight is from about ~~about~~ 0.3 percent to about 4.0 percent of the total tablet weight.

Claims 8 to 10 (cancelled)

11. (Currently amended) ~~A~~ **The** tablet ~~as in~~ **of** claim 6 wherein the amount of lubricant **zinc stearate** by weight is from about ~~about~~ 0.3 percent to about 4.0 percent of the total tablet weight.

12. (Currently Amended) ~~A pharmaceutical tablet comprising fosinopril sodium and the lubricant zinc stearate in the amount by weight from about 0.3 percent to about 4.0 percent of the total tablet weight and wherein the presence of zinc stearate results in a significant reduction in products of degradation for the tablet in comparison to other known lubricants such as magnesium stearate, and calcium stearate.~~ **A pharmaceutical tablet comprising fosinopril sodium and zinc stearate as lubricant in an amount by weight from about 0.3% to about 4.0% of the total weight, wherein the rate of degradation of fosinopril sodium is reduced relative to the same fosinopril sodium tablet but comprising as lubricant magnesium stearate or calcium stearate instead of zinc stearate as lubricant.**

13. (Previously presented) The tablet of claim 12 further comprising at least one excipient selected from lactose, microcrystalline cellulose, starch, crosscarmellose sodium, sodium starch glycolate, crospovidone, or colouring.

14. (New) A method of reducing degradation of fosinopril sodium when it is formulated into a dosage form with a lubricant, the method comprising formulating fosinopril sodium using zinc stearate as lubricant.

15. (New) A pharmaceutical tablet comprising fosinopril sodium and zinc stearate as lubricant, wherein the degradation of fosinopril sodium in the tablet is reduced relative to the same fosinopril sodium tablet but comprising, magnesium stearate, or calcium stearate as lubricant instead of zinc stearate as lubricant.

16. (New) The tablet of claim 15 further comprising lactose.

17. (New) The tablet of claim 15 or 16 wherein the amount of zinc stearate by weight is from about 0.3% to about 4.0% of the total tablet weight.

18. (New) The tablet of claim 17 further comprising at least one excipient selected from lactose, microcrystalline cellulose, starch, crosscarmellose sodium, sodium starch glycolate, crospovidone, or colouring.